Company / R&D Expense
LIXTE BIOTECHNOLOGY HOLDINGS, INC. R&D Expense History
FY2011-FY2015 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$1.1M
FY2015
5-year range
$445.5K / $1.3M
FY2011-FY2015
Trend
+10.5%
vs FY2014
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $1M to $1M over the past 3 years.
Based on SEC 10-K filings.
$1M in FY2015 with a 3-year CAGR of -5.7%.
Declined from $1M to $1M over the past 3 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -5.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -5.7%, indicating a declining trend.
- In FY2015, r&d expense increased 10.5% year-over-year.
Company context
Key Data Points
- Altman Z-Score -11.44 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2015 | $1.1M | +10.5% |
| FY2013 | $1.0M | -24.2% |
| FY2012 | $1.3M | +199.6% |
| FY2011 | $445.5K | - |
As of FY2015 · SEC 10-K · Updated Jun 24, 2026